4 April 2022 - The TGA has approved Vumerity (diroximel fumarate).

Vumerity is indicated in patients with relapsing multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability.

Read TGA prescription medicine decision summary for Vumerity